科华生物股价下跌2.49% 公司聘任新财务总监

Core Viewpoint - KHBio's stock price closed at 6.66 yuan on July 31, reflecting a decrease of 0.17 yuan or 2.49% from the previous trading day [1] Group 1: Company Overview - KHBio operates in the medical device industry, focusing on the research, production, and sales of in vitro diagnostic reagents and medical instruments [1] - The company's product range includes clinical testing, immunodiagnostics, and molecular diagnostics [1] Group 2: Recent Developments - On July 31, KHBio's board approved the appointment of Zang Xianfeng as the new Chief Financial Officer [1] - The company announced that its ultra-high-performance liquid chromatography-tandem mass spectrometry system is an open system, which, when used with the company's mass spectrometry reagents, enhances the stability and accuracy of test results [1] - KHBio revealed a collaboration with Waters Corporation to launch two products that have received national medical device registration certificates, utilizing a "dual-brand" model to create an integrated platform [1] Group 3: Market Activity - On July 31, KHBio experienced a net outflow of main funds amounting to 17.06 million yuan, representing 0.5% of its circulating market value [1]